Abstract 3180: Targeting LRG1 to normalize tumor vasculature and enhance therapeutic efficacy
Authors: Greenwood John , Camilli Carlotta , Pilotti Camilla , Bowers Chantelle E. , Moss Stephen E. 
Published: June 2022

In recent years improving tumor vascular function, to render the tumour microenvironment less permissive and to improve delivery of therapeutics, has gained traction due to a growing body of supportive evidence. Identifying suitable targets that are tractable, ubiquitous and safe, however, has proven to be more challenging. Almost a decade ago we reported that a secreted glycoprotein, leucine-rich alpha-2-glycoprotein 1 (LRG1), was induced in ocular neovascular complications and contributed to the formation of dysfunctional neovessels1. More recently, we have reported that LRG1 is expressed in experimental and human tumors, and that its inhibition with a function-blocking antibody improves outcome in multiple primary2 and metastatic3 models of cancer. Crucially, we found that LRG1 blockade normalizes tumor vessels and enhances the efficacy of cisplatin, adoptive T cell and checkpoint inhibitor therapy, and that a humanized version of our blocking antibody named Magacizumab effectively inhibits tumour growth both alone and as an antibody-drug-conjugate4.Using animal models and in vitro assays we present here further data in support of LRG1 as a promising target for the treatment of solid cancers. We have further investigated the effects of LRG1 blockade on immune cell infiltration using flow cytometric and immunohistochemical analysis. In subcutaneous B16 melanoma-bearing mice treated with a PD1 checkpoint inhibitor, antibody blockade of LRG1 significantly enhanced the infiltration of CD3+ and CD8+ T cells, with the latter exhibiting a more activated phenotype as evidenced by higher GrzB, reduced PD1hi expression and increased proliferation. We also observed a reduction in the Tregs:Th ratio and a higher number of MHCII+ cells. These outcomes were also observed in LLC tumors alongside a reduction in the number of infiltrated neutrophils. In preliminary studies, where we investigated LRG1 blockade in the Rag1 mouse, we observed no effect suggesting that the downstream mode of action is mediated by impacting the immune system. Finally, to test the development of our humanized anti-LRG1 antibody Magacizumab, that only recognizes human LRG1, we demonstrated its efficacy in B16F0 tumors grown in a human LRG1 knock-in mouse. These studies provide compelling evidence that LRG1 is a novel, legitimate and potentially efficacious target for the treatment of various human solid cancers. References:Wang X et al. (2013). LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling. Nature 499:306-311. O’Connor MN et al. (2021). LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med 2:1231-1252.Singhal M et al. (2021). Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis. Sci Transl Med. 609:eabe6805. Javaid F et al., (2021). Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chem. Biol. 2:1206-1220.

Citation Format: John Greenwood, Carlotta Camilli, Camilla Pilotti, Chantelle E. Bowers, Stephen E. Moss. Targeting LRG1 to normalize tumor vasculature and enhance therapeutic efficacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3180.